as did 96% of those who stayed on their daily oral regimen. The follow-upATLAS-2M studyshowed that every-other-month dosing works as well as once-monthly administration. (ViiV has requested FDA approval of
In January 2021, the Food and Drug Administration (FDA)approved once-monthly Cabenuva, from ViiV Healthcare, as the first complete injectable antiretroviral regimen that does not require daily pills. The new treatment is approved for people with an undetectable viral load on their current therapy w...
Cabenuva is administered as two injections into your buttock muscles monthly or every other month. Before your doctor administers Cabenuva injections they will need to determine that you can tolerate the active ingredients, which are cabotegravir and rilpivirine. At least 28 days before your first ...
The US FDA approval of long-acting cabotegravir and rilpivirine for use every two months is based on the global ATLAS-2M phase IIIb trial results, which demonstrated that every-two-month dosing was non-inferior to once-monthly dosing.2Non-inferiority was determined by ...
“The once-monthly injections of CABENUVA™ showed comparable efficacy to daily oral antiretroviral treatment in maintaining viral suppression,” said David Alain Wohl*, M.D., Professor of Medicine, Division of Infectious Diseases, University of North Carolin...
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that Health Canada has approved CABENUVA, the first and only once-monthly, complete long-acting regimen for the treatment of ...
The once-monthly and every-two-months version of cabotegravir and rilpivirine injectable treatment has been approved for adults by the European Commission, Health Canada, the Australia Therapeutic Goods Administration,...
ViiV Healthcare and Janssen have announced the Health Canada approval of Cabenuva as a once-monthly, long-acting therapy for adults with HIV-1 infection.
Cabenuva was approved by the US FDA in January 2021 as a once-monthly, long-acting regimen for the treatment of HIV-1 infection in virologically suppressed adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's 25-year commitment ...